PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsRopivacaine
Ropivacaine
Naropin, Ropivacaine (ropivacaine) is a small molecule pharmaceutical. Ropivacaine was first approved as Naropin on 1996-09-24. It is used to treat postoperative pain in the USA. It is known to target sodium channel protein type 5 subunit alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Naropin, Ropivacaine (discontinued: Naropin, Ropivacaine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ropivacaine hydrochloride
Tradename
Company
Number
Date
Products
NAROPINFresenius KabiN-020533 RX1996-09-24
11 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
naropinNew Drug Application2024-09-06
naropin naropinNew Drug Application2018-08-02
readyfusor ropivacaineExport only2018-06-22
ropidexunapproved drug other2024-10-04
ropivacaine hydrochlorideANDA2024-10-08
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
postoperative painD010149G89.18
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Ropivacaine Hydrochloride, Naropin, Fresenius Kabi Usa
78578022026-11-28DP
78287872025-10-18DP
81629152024-05-23DP
ATC Codes
N: Nervous system drugs
N01: Anesthetics
N01B: Local anesthetics
N01BB: Amide local anesthetics
N01BB09: Ropivacaine
HCPCS
Code
Description
J2795
Injection, ropivacaine hydrochloride, 1 mg
Clinical
Clinical Trials
1828 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Postoperative painD010149G89.18112543172272517
PainD010146EFO_0003843R5287143960125
Replacement arthroplasty kneeD019645365413991
AnalgesiaD00069865145075
Bone fracturesD050723EFO_0003931T14.8224233869
Nerve blockD009407112194366
Local anesthesiaD000772235163964
OsteoarthritisD010003EFO_0002506M15-M19143272961
AnesthesiaD000758134153758
Acute painD059787R5233393653
Show 247 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8023712
Spinal anesthesiaD0007751179
Synovial cystD013581M71.3279
HepatectomyD006498189
HypotensionD007022EFO_0005251I95167
Wrist fracturesD000092503347
Musculoskeletal diseasesD0091403247
Low back painD017116HP_0003419M54.51146
Urinary bladder neoplasmsD001749C67145
Post-dural puncture headacheD051299145
Show 44 more
Indications Phases 2
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Arteriovenous fistulaD001164Q27.3145
Male circumcisionD002944EFO_0003953134
Chronic kidney failureD007676EFO_0003884N18.9134
Multiple fracturesD000069076HP_0002757112
Vulvar diseasesD014845112
Uterine myomectomyD063186112
Plantar fasciitisD036981EFO_1001909M72.211
FasciitisD005208HP_0100537M72.911
Clostridium botulinum type aD04701311
Coronary occlusionD054059I2111
Show 2 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Aortic valve stenosisD001024HP_000165044
Thoracic injuriesD013898S20-S2944
Diabetic footD017719EFO_100145944
AcrodyniaD000170EFO_100175644
Cognitive dysfunctionD060825HP_0001268G31.8444
Esophageal neoplasmsD004938C1533
Ventral herniaD006555EFO_1001866K4333
CryptorchidismD003456EFO_0004562Q53.133
CholecystitisD002764HP_0001082K8133
Tibial meniscus injuriesD00007060033
Show 207 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRopivacaine
INNropivacaine
Description
(S)-ropivacaine is a piperidinecarboxamide-based amide-type local anaesthetic (amide caine) in which (S)-N-propylpipecolic acid and 2,6-dimethylaniline are combined to form the amide bond. It has a role as a local anaesthetic. It is a piperidinecarboxamide and a ropivacaine.
Classification
Small molecule
Drug classlocal anesthetics
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Identifiers
PDB
CAS-ID84057-95-4
RxCUI
ChEMBL IDCHEMBL1077896
ChEBI ID8890
PubChem CID175805
DrugBankDB00296
UNII ID7IO5LYA57N (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
SCN5A
SCN5A
Organism
Homo sapiens
Gene name
SCN5A
Gene synonyms
NCBI Gene ID
Protein name
sodium channel protein type 5 subunit alpha
Protein synonyms
cardiac tetrodotoxin-insensitive voltage-dependent sodium channel alpha subunit, hH1, Sodium channel protein cardiac muscle subunit alpha, Sodium channel protein type V subunit alpha, sodium channel, voltage-gated, type V, alpha subunit, Voltage-gated sodium channel subunit alpha Nav1.5
Uniprot ID
Mouse ortholog
Scn5a (20271)
sodium channel protein type 5 subunit alpha (Q9JJV9)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 12,421 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,520 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use